Key result
Bioactivation of nitroglycerin, essential to its vascular action in treating ischemic heart disease, is catalyzed by mitochondrial aldehyde dehydrogenase.
This editorial discusses the discovery that mitochondrial aldehyde dehydrogenase catalyzes the bioactivation of nitroglycerin, providing a new mechanistic understanding of this classic angina treatment.
Even after more than a century it is not completely understood how nitroglycerin (GTN) functions in the treatment of ischemic heart disease (angina pectoris). Recent work by Jonathan Stamler and co-workers (Duke University) now suggests that bioactivation of nitroglycerin, which is essential to the vascular action of the drug, is catalyzed by mitochondrial aldehyde dehydrogenase (mtALDH; see scheme). These important findings are discussed with special emphasis given to their pharmacological and clinical implications.
No takes yet. Share an insight, caveat, or question.
Bernd Mayer (2003) conducted an editorial in Ischemic heart disease (angina pectoris). Nitroglycerin (GTN) was evaluated. Bioactivation of nitroglycerin, essential to its vascular action in treating ischemic heart disease, is catalyzed by mitochondrial aldehyde dehydrogenase.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: